TWST - Twist Bioscience GAAP EPS of -$1.01 beats by $0.13 revenue of $63.74M beats by $3.05M

2023-08-04 07:32:09 ET

• Twist Bioscience press release ( NASDAQ: TWST ): Q3 GAAP EPS of -$1.01 beats by $0.13 .
• Revenue of $63.74M (+13.6% Y/Y) beats by $3.05M .
• Total orders received for the third quarter of fiscal 2023 were $63.8 million compared to $59.7 million for the same period of fiscal 2022.

• For the full fiscal year 2023, Twist provided the following updated financial guidance:

  • Revenue is expected to be approximately $241 million to $242 million, compared to previous guidance of $235 million to $238 million
  • Gross margin for fiscal 2023 is expected to be 36%, at the high end of the range of previous guidance of 35-36%
  • Operating expenses including R&D and SG&A are expected to be approximately $308 million, compared to previous guidance of $313 million to $319 million
  • Capital expenditure is expected to be approximately $35 million, compared to previous guidance of $40 million
  • FY23 Year End Cash is projected to be $325 million, compared to previous guidance of $320 million

• For the fourth quarter of fiscal 2023, Twist provided the following financial guidance:

  • Revenue is expected to be approximately $63 million to $64 million, compared to previous guidance of $62 to $63 million
  • Gross margin is expected to be approximately 36%
  • R&D expense is expected to be approximately $26 million
  • SG&A expense is expected to be approximately $47 million
  • Restructure expense is expected to be approximately $1 million

For further details see: